Overview
Specifications
| Reagent | in vivo-jetPEI® |
|---|---|
| Molecule delivered | DNA |
| Applications | in vivo functional studies (overexpression, knock-down, CRISPR genome editing) |
| Targeted organs | All organs |
| Injection routes | Various systemic and local administration routes |
| Number of transfections | eg. 100 µl of in vivo-jetPEI® delivery reagent is sufficient to perform 15 to 25 intravenous injections in mouse. |
| Storage | Store in vivo-jetPEI® at -20 ± 5 °C. |
| Provided with | 10% glucose solution |
Summary
in vivo-jetPEI® is the most advanced in vivo transfection reagent for safe and efficient in vivo delivery of DNA, si/miRNA and other oligonucleotides in animal models. With a track record of over 700 publications, in vivo-jetPEI® is the consensual in vivo transfection method for in vivo functional studies, cancer research and immunization/vaccination.
Table 1: Range of in vivo-jetPEI® quality grade reagents for each step of in vivo DNA, si/miRNA transfection. in vivo-jetPEI® is available as an R&D grade for fundamental research and proof of concept studies. For preclinical biodistribution and toxicology studies and early phase clinical studies, we supply a higher preclinical grade in vivo-jetPEI®. GMP in vivo-jetPEI® is the highest quality grade available to meet quality demands in Human clinical trials.
Ordering information
| Reference Number | Amount of reagent | Amount of 10% glucose solution |
|---|---|---|
| 101000040 | in vivo-jetPEI® 0.1 mL | 10 ml |
| 101000030 | in vivo-jetPEI® 0.5 mL | 2 x 10 ml |
Related Products
Description
Polyvalent: in vivo delivery of DNA, si/sh/miRNA nucleic acid in any animal model including mice
The easiness of use and versatility of in vivo-jetPEI® allows scientists to perform gene function studies by overexpressing or downregulating a gene in any organ/tissue of interest. in vivo-jetPEI® is polyvalent: it is suitable for the delivery of nucleic acid (plasmid DNA, siRNA, shRNA, miRNA and oligonucleotides) in any animal model (mice, rat, guinea pig, dog, rabbit, monkey, etc…). Numerous Scientific publications demonstrate the successful delivery of each type of nucleic acid in different animal model.
in vivo-jetPEI® has already been used to target a wide range of organs by systemic and local injection routes. Local administration routes include subcutaneous tumor, intracerebral or intra-articular injections and topical application. The injection route largely determines the targeted organs. For example, upon intravenous injection, in vivo-jetPEI®-mediated DNA delivery leads to gene expression mainly in the lung but also in the liver, pancreas, spleen, kidney, heart, bladder and artery. Conversely, upon intraperitoneal injection, the gene of interest will be expressed in the ovary, pancreas, diaphragm, uterus and stomach (Fig. 1). To achieve organ specific gene expression, cell-specific promoters can be combined with the choice of a local injection route to restrict gene expression to an organ/tissue. Guidelines for systemic and most local injection routes are available.
Fig. 1: Organs targeted following systemic nucleic acid delivery using in vivo-jetPEI® in mice. Complexes were formed using 40 μg or 100 μg of luciferase expressing plasmid and in vivo-jetPEI® at an N/P ratio of 8, in 200 μl or 1 ml of 5% glucose and injected either through retro-orbital sinus (IV) or intraperitoneally (IP), respectively. 24 hours after injection, different organs were extracted and luciferase expression was measured or live imaging was performed using IVIS system (Perkin Elmer).
Easy-to-use: two-step protocol
in vivo-jetPEI® is the reagent of choice to deliver DNA, si/sh/miRNA nucleic acid using most systemic and local injection routes. The protocol is easy to use and similar to a classical in vitro transfection: the nucleic acid and in vivo-jetPEI® reagent are mixed and directly injected into the animal model (Fig. 2).
Fig 2: in vivo-jetPEI® protocol in mice. This two-step protocol is compatible with direct injection of in vivo-jetPEI®/nucleic acid nanoparticles though any systemic or local administration routes.
Our delivery experts are available to adapt your protocol to your animal model and send you the relevant literature.
contact the Scientific Support
Renowned: Most advanced in vivo delivery technology for cancer research, immunization and vaccination
in vivo-jetPEI® is a powerful polymer-based reagent with unique properties. In the provided complexation solution, in vivo-jetPEI® condenses any nucleic acid into stable nanoparticles of ca. 50 nm diameter (Fig 1). These nanoparticles are sufficiently small to efficiently diffuse within tissues and enter cells by endocytosis, while protecting naked nucleic acids from degradation. At the cellular level, in vivo-jetPEI facilitates both endosomal escape using the proton sponge mechanism (Akinc et al. (2005), J Gene Med 7: 657), and crossing of the nuclear membrane (Brunner et al. (2002), Mol Ther 5: 80).
Fig. 3 in vivo-jetPEI® forms small spherical particles with plasmid DNA. in vivo-jetPEI®/DNA complexes are prepared in 5% glucose solution at N/P ratio of 10. Complexes were added on a carbon covered grid and stained with uranyl acetate. Observation was carried out under a TEM. Bar is 100 nm. Complexes produced in glucose solution are discrete spheres having a mean size of 50 +/- 30 nm (Courtesy J-S Remy, Laboratoire Chimie Génétique, CNRS UMR 7514, Illkirch, France).
Successful: Used from fundamental research to Human clinical trials
Due to its reliability, in vivo-jetPEI® has been selected as a delivery vector for several drug development programs due to its safety and delivery efficiency. There are currently several ongoing clinical trials for cancer therapies, vaccination and immunization using higher quality grade GMP in vivo-jetPEI®.
FAQ
If you have any questions regarding in vivo-jetPEI®, please visit our dedicated Frequently asked questions or contact us.
Applications
in vivo functional studies
in vivo-jetPEI® is perfectly suited to study gene function in vivo and provides the easiest method for the validation of in vitro functional studies into animals.
Cancer Therapy
in vivo-jetPEI®-based nucleic acid delivery is now widely used for tumor growth inhibition studies. As an example, the delivery of a modified siRNA against Cyclin B1 with in vivo-jetPEI® inhibits the formation of lung metastases (Fig. 4A) and in vivo-jetPEI® mediated delivery of a modified siRNA against Survivin prevents the growth of a tumor xenograft model (Fig. 4B).
Fig. 4: Tumor growth inhibition following in vivo-jetPEI® mediated delivery of modified siRNAs. (A) Mice were injected intravenously with TSA-Luc cells forming exclusively lung metastases. 2 days after cell injection, the mice were treated intravenously with 1 mg/kg of STICKY siRNA™ against cyclin B1 (N/P=12.5). Bioluminescence imaging was performed 10 days after cell injection. Data from Bonnet et al., (2013), J Control Release 170(2) :183-90. (B) Mice bearing tumor xenografts were treated intravenously with 1 mg/kg of STICKY siRNA™ against Survivin (N/P=12.5). Tumor growth was monitored after each treatment and represented as a mean tumor volume ± SEM. Data from Kedinger et al., (2013), BMC Cancer 13:338.
Immunization/Vaccination
Following in vivo administration of plasmid DNA formulated with in vivo-jetPEI®, the expressed protein can elicit the induction of a robust and persistent immune response, hence protecting animals from different viruses or pathogens challenge.
in vivo gene editing using CRISPR/Cas9 system
in vivo-jetPEI®-mediated delivery of CRISPR/Cas9 system targeting tumor suppressor genes provides a flexible and effective method to investigate somatic loss-of-function alterations and their influence on tumorigenesis.
📰 Download our Researcher’s guide to Genome editing!
Quality
Polyplus-transfection® is ISO 9001 Quality Management System accredited since 2002; this level of certification assures global customers that the supplier has established reliable and effective processes for product development, manufacturing, sales and customer support.
Each batch of in vivo-jetPEI® reagent is tested for conformity to established Quality Controls and relevant specifications. A Certificate of Analysis is provided with each vial of reagent
Testimonials
Protocol
In order to download a product protocol or a certificate of analysis, please create an account on Polyplus-transfection® Portal.
Why would you need to create an account?
In this personal area you will have access to:
- Product Protocols
- Certificates of Analysis
- Exclusive webinars/articles
- And surprise features!
Other files
Related blog posts
Bibliography
| Cell Line | in vitro in vivo | Delivered Molecule | Reagent | Results & Citations | |
|---|---|---|---|---|---|
| B16-F10 | in vitro / in vivo | DNA | in vivo-jetPEI, jetPEI | Ortiz, R. et al. (2009) J Mol Med 87, 899-911 The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo | More details |
| - | in vivo | modified siRNA | in vivo-jetPEI | Poeck, H. et al. (2008) Nat Med 14, 1256-63 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma | More details |
| - | in vivo | shRNA plasmid | in vivo-jetPEI | Rotgers, E. et al. (2014) Cell Death Dis 5, e1274 Retinoblastoma protein (RB) interacts with E2F3 to control terminal differentiation of Sertoli cells | More details |
| - | in vivo | mimic miRNA | in vivo-jetPEI | Song, F. et al. (2014) Clin Cancer Res 20, 878-89 Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family | More details |
| - | in vivo | DNA | in vivo-jetPEI | Tian, D. et al. (2008) J Asthma 45, 715-21 Therapeutic effect of intratracheal administration of murine IL-4 receptor antagonist on asthmatic airway inflammation | More details |
| - | in vivo | siRNA | in vivo-jetPEI | Wang, S. et al. (2008) Hypertension 52, 484-90 Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure | More details |
| - | in vivo | DNA | in vivo-jetPEI | Wong, S. P. et al. (2011) Gene Ther 18, 82-7 Non-viral S/MAR vectors replicate episomally in vivo when provided with a selective advantage | More details |
| - | in vivo | shRNA plasmid | in vivo-jetPEI | Xu, K. et al. (2010) Cancer Gene Ther 17, 212-22 Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis | More details |
| - | in vivo | shRNA plasmid | in vivo-jetPEI | Zhang, F. et al. (2012) Cell Rep 2, 1272-85 Proliferative and survival effects of PUMA promote angiogenesis | More details |
| - | in vivo | DNA | in vivo-jetPEI | Zhu, Q. et al. (2012) Biochim Biophys Acta 1822, 936-41 Overexpression of HIF-1alpha transgene in the renal medulla attenuated salt sensitive hypertension in Dahl S rats | More details |